Heart Failure
Conditions
Brief summary
Subjects will include patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab; and who have one or more risk factors for cardiovascular disease. Subjects will received an extra echocardiogram to determine if heart problems can be detected earlier.
Detailed description
* Patients scheduled for potentially cardiotoxic chemotherapy would receive a baseline echocardiogram as per standard protocol which should be covered by the routine insurance * Follow-up with an extra echocardiogram for research purposes would be performed after 2 cycles of that chemotherapy - supplied by the study * Clinical assessment at 3 to 6 months including repeat echocardiography as per standard care with the research question as whether any differences in strain pattern between pre-chemo and post 2 cycles studies all identify patients who are more likely to have cardiac issues later. * Patients will have standard of care visits at 3 month, 6 month and 12 month and will be evaluated for cardiac status and survival. * Patient records will be reviewed at 5 years to check cardiac status and survival.
Interventions
OTHERExtra echocardiogram
Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
Sponsors
The Guthrie Clinic
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males and females 18 years and above * Willing and able to provide consent * Able to read * Patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab. * Patients at increased risk of cardiotoxicity with one or more risk factors for heart disease: * LVEF 50-54% by baseline echocardiogram * Age ≥ 65 * BMI ≥ 30 kg/m2 * Current or prior anti-hypertensive therapy * Diagnosis of coronary artery disease (CAD) * Diabetes Mellitus * Atrial fibrillation/flutter
Exclusion criteria
* Children * Patients who are pregnant * Only single encounter without follow up * Cancer diagnosis other than breast or hematological cancer * Chemotherapy treatment other than anthracycline or trastuzumab * No prior chemotherapy treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in left ventricular ejection fraction (LVEF) | through study completion, an average of 1 year | a decrease in LVEF of ≥10 percentage points from baseline to a value of \< 50% OR a decrease of LVEF by ≥ 5 percentage points from baseline to LVEF \<50% for patients who have a baseline LVEF of 50-54% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival status | through study completion, an average of 1 year | alive or deceased |
| Change in symptoms that may be indicative of heart failure | through study completion, an average of 1 year | Presence of absence of symptoms |
| Change in treatment that may be indicative of heart failure | through study completion, an average of 1 year | Presence or absence of treatment for heart failure |
| Change in strain echo that may be indicative of heart failure | through study completion, an average of 1 year | Presence or absence of heart failure by imaging |
Outcome results
None listed